📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-24 18:08
477 analysed today
FollowTelegram
477
Today
149,878
All-time analysed
42,959
Positive
6,669
Negative
91,543
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
13.7% YoY Revenue Growth in Q1 FY27; First Biologics Order Secured
Vimta Labs reported a resilient Q1 FY27 with total income reaching ₹112.9 cr, a 13.7% increase YoY. EBITDA margins remained strong at 36.4%, while PAT grew 11.4% YoY to ₹21.0 cr. A key milestone was securing the first order for the newly operationalized Biologics facility, marking entry into a high-margin segment. Management maintained a full-year growth guidance of 20-25%, despite geopolitical headwinds in the food testing export business.
Confidence: HIGH
What changedThe company has transitioned from the investment phase to the operational phase in its Biologics business and integrated its environment division into the food division for operational efficiency.
Why it mattersEntry into Biologics and defense electronics testing represents a shift toward higher-value, specialized services which can sustain the company's industry-leading EBITDA margins (36.4%) and utilize the expanded 600,000 sq. ft. capacity.
Q1 FY27 Total Income: ₹112.9 crYoY Revenue Growth: 13.7%EBITDA Margin: 36.4%PAT: ₹21.0 crCash and Equivalents: ₹62.82 crQ1 Revenue vs FY25 Annual Revenue: ~44%
📅 Short termThe stock may react positively to the margin expansion and the milestone of the first Biologics order, though seasonal Q4-to-Q1 flat sequential growth is noted.
📈 Long termThe company is structurally positioned for growth through its 600,000 sq. ft. lab capacity and diversification into high-growth areas like biologics and defense electronics.
⚠ Risk flags
- Geopolitical issues impacting food export testing volumes
- Impact of new labor laws on operating costs
- Rupee appreciation affecting export realizations
Key Highlights
Total income for Q1 FY27 rose to ₹112.9 cr from ₹99.3 cr in the previous year's quarter.
EBITDA increased by 16% YoY to ₹41.1 cr, with margins expanding to 36.4%.
Secured the first order for Biologics services and operationalized the specialized facility.
Maintained a net debt-free balance sheet with cash and cash equivalents of ₹62.82 cr.
Management reaffirmed a full-year revenue growth target of 20% to 25%.
👀 What to Watch
Watch for the revenue contribution and margin profile of the Biologics segment in upcoming quarters, and monitor if food export volumes recover from Middle East geopolitical disruptions.
13.7% YoY Revenue Growth in Q1 FY27; EBITDA Margins Expand to 36.4%
Vimta Labs reported a steady Q1 FY27 with total income rising 13.7% YoY to ₹112.9 crore. EBITDA grew 16% YoY to ₹41.1 crore, with margins expanding to 36.4% from 35.7% in the year-ago period. Net profit increased 11.4% YoY to ₹21.0 crore, supported by strong traction in Pharmaceutical Research and Testing. The company also operationalized its Biologics contract research and development services (CRADS) during the quarter, marking an entry into high-margin specialized segments.
Confidence: HIGH
What changedVimta Labs reported its Q1 FY27 financial results and announced the commencement of operations in its Biologics CRADS division.
Why it mattersThe results demonstrate the company's ability to maintain high operating margins (36%+) while diversifying into higher-value biologics services, which reduces reliance on the currently challenged food testing segment.
Total Income (Q1 FY27): ₹112.9 crYoY Revenue Growth: 13.7%EBITDA Margin: 36.4%PAT (Q1 FY27): ₹21.0 crQ1 Revenue vs TTM Revenue: 44.1%
📅 Short termThe stock may see positive sentiment due to double-digit revenue and profit growth alongside margin expansion in a challenging global environment.
📈 Long termThe expansion into Biologics and large molecule research is structurally significant as these segments typically offer higher pricing power and could drive long-term margin improvement.
⚠ Risk flags
- Global uncertainties impacting the Food Testing division
- Regulatory compliance risks inherent in clinical research services
Key Highlights
Total Income for Q1 FY27 reached ₹1,129 million, up 13.7% from ₹993 million in Q1 FY26.
EBITDA margins improved to 36.4% compared to 35.7% in the same quarter last year.
Net Profit (PAT) stood at ₹210 million, an 11.4% increase over the previous year's ₹189 million.
Commenced operations in Biologics contract research and development services (CRADS).
Successfully completed a regulatory audit from Ukraine, maintaining compliance standards.
👀 What to Watch
Watch for the revenue contribution and margin impact from the newly launched Biologics CRADS segment in upcoming quarters, and monitor the recovery of the food testing division which is currently facing global headwinds.
Vimta Labs Q1 FY27: 11% YoY Revenue Growth to ₹112.9 Cr with 36.4% EBITDA Margin
Vimta Labs reported a steady Q1 FY27 with total income reaching ₹112.9 Cr, an 11.1% increase YoY. Profitability remained strong with an EBITDA margin of 36.4% and PAT growing 11% YoY to ₹21 Cr. The company continues its capital expenditure program, investing ₹18 Cr during the quarter to support its 600,000 sq. ft. laboratory infrastructure. With a near-zero debt-to-equity ratio of 0.01, the company is well-positioned to fund its expansion into high-margin segments like Biologics and Defense electronics testing.
Confidence: HIGH
What changedThe company has transitioned to a focused Contract Research and Testing (CRT) model following the divestment of its diagnostics business, showing improved margin profiles.
Why it mattersThe consistent 36%+ EBITDA margins indicate strong pricing power and operational efficiency in specialized testing services, which are critical for the pharma and food export industries.
Total Income (Q1 FY27): ₹112.9 CrEBITDA Margin: 36.4%PAT (Q1 FY27): ₹21.0 CrQuarterly Capex: ₹18.0 CrCapex vs Market Cap: ~1.4%Debt-to-Equity: 0.01
📅 Short termThe stock may react positively to the double-digit growth in revenue and profit while maintaining high margins despite a challenging global environment.
📈 Long termStructural growth is supported by the expansion into Biologics and Defense electronics, sectors with high entry barriers and better margins than traditional testing.
⚠ Risk flags
- Regulatory risks associated with USFDA and WHO audits
- Dependence on timely procurement of imported specialized equipment
- Availability of subjects for clinical trials
Key Highlights
Total Income grew 11.1% YoY to ₹112.9 Cr from ₹99.3 Cr in Q1 FY26.
EBITDA margin improved to 36.4% from 35.7% in the same quarter last year.
Net Profit (PAT) stood at ₹21 Cr, representing an 11% YoY growth.
Quarterly Capex cash outflow was ₹18 Cr, focused on expanding lab capabilities.
Maintained a very low Debt-to-Equity ratio of 0.01 as of the latest annual reporting.
👀 What to Watch
Investors should monitor the ramp-up of the newly added 200,000 sq. ft. capacity and the revenue contribution from the high-margin Biologics and Electronics testing segments in upcoming quarters.
Vimta Labs Q1 FY27: 11.8% Revenue Growth to ₹109.07 Cr; PAT Rises to ₹21.04 Cr
Vimta Labs reported a steady performance for Q1 FY27, with revenue from operations increasing 11.8% YoY to ₹109.07 Cr. Net profit grew by 11.4% YoY to ₹21.04 Cr, maintaining a healthy Profit Before Tax (PBT) margin of 25.1%. The company continues to operate as a single-segment entity focused on Contract Research and Testing Services. Additionally, the board approved the grant of 40,500 ESOPs to eligible employees on July 20, 2026.
Confidence: HIGH
What changedVimta Labs released its Q1 FY27 financial results, showing consistent double-digit growth in revenue and profit compared to the previous year's corresponding quarter.
Why it mattersThe results demonstrate the company's ability to maintain profitability and margins (PBT at 25%) while scaling its contract research operations, despite a slight sequential dip in revenue compared to Q4 FY26.
Revenue (Q1 FY27): ₹109.07 CrNet Profit (Q1 FY27): ₹21.04 CrYoY Revenue Growth: 11.8%PBT Margin: 25.1%ESOPs Granted: 40,500 units
📅 Short termThe stock is likely to see neutral-to-positive sentiment as the results reflect steady execution and stable margins in line with historical performance.
📈 Long termLong-term value depends on the company's ability to leverage its expanded infrastructure and pivot towards higher-margin specialized testing services like biologics and defense electronics.
⚠ Risk flags
- Rising employee and operational costs
- Regulatory compliance risks inherent in USFDA/GXP audited facilities
Key Highlights
Revenue from operations grew 11.8% YoY to ₹109.07 Cr from ₹97.56 Cr in Q1 FY26.
Net Profit for the quarter increased 11.4% YoY to ₹21.04 Cr compared to ₹18.89 Cr.
Total expenses rose to ₹84.55 Cr, driven by higher depreciation (₹12.55 Cr) and other expenses (₹19.67 Cr).
Employee benefit expenses included a non-cash charge of ₹0.846 Cr related to stock options.
Board approved the grant of 40,500 new ESOP options under the VLESOP-2021 plan.
👀 What to Watch
Investors should monitor the utilization levels of the recently expanded 600,000 sq. ft. lab capacity and the growth trajectory in high-margin biologics and defense electronics testing.
₹2 per share dividend paid for FY 2025-26 by Vimta Labs
Vimta Labs Limited has completed the payment of its final dividend for the financial year 2025-26. The dividend of ₹2 per equity share (face value ₹2) was distributed to eligible shareholders on July 4, 2026, following approval at the Annual General Meeting. Based on the TTM EPS of ₹22.07, this represents a dividend payout ratio of approximately 9%. The company continues to maintain a strong balance sheet with a debt-to-equity ratio of 0.01.
Confidence: HIGH
What changedThe company has transitioned from the recommendation stage to the actual disbursement of the FY26 dividend to shareholders.
Why it mattersThe payment confirms the company's commitment to shareholder returns while operating with high margins (OPM 34.1%) and minimal debt (₹3 Cr).
Dividend per share: ₹2Face Value: ₹2Payment Date: 04 July 2026Dividend Payout Ratio (TTM): ~9.06%
📅 Short termNeutral, as the dividend payment was previously recommended and expected by the market; no immediate impact on stock price is anticipated from this procedural update.
📈 Long termLimited; the consistent dividend payment reflects financial stability but the long-term value remains tied to the expansion into defense electronics and biologics testing.
Key Highlights
Dividend of ₹2 per equity share paid to eligible shareholders
Face value of the equity shares is ₹2 each
Payment completed on 04 July 2026 following AGM approval
Dividend pertains to the full financial year 2025-26
👀 What to Watch
Investors should monitor the company's utilization of its expanded 600,000 sq. ft. lab capacity in upcoming quarterly results to see if it translates to the targeted 20% growth rate.
Vimta Labs Shareholders Approve Rs 2 Dividend and Key Leadership Re-appointments at 36th AGM
Vimta Labs Limited successfully concluded its 36th Annual General Meeting on June 25, 2026, with all proposed resolutions receiving overwhelming shareholder approval. A key outcome for investors is the approval of a Rs 2 per equity share dividend for the financial year ended March 31, 2026. Shareholders also confirmed the re-appointment of Dr. S.P. Vasireddi as Executive Chairman and Mr. Harriman Vungal as Executive Director Operations, ensuring leadership continuity. The voting results showed strong consensus, with most resolutions passing with over 99.99% of votes in favor.
Key Highlights
Approved a dividend of Rs 2 per equity share for the financial year ended March 31, 2026.
Dr. S.P. Vasireddi re-appointed as Executive Chairman via special resolution with 99.99% favor.
Mr. Harriman Vungal re-appointed as Executive Director Operations with 99.99% favor.
Total of 17,103,073 votes were polled out of 44,669,355 total shares held.
Ratification of cost auditors' remuneration for FY 2024-25 and FY 2025-26 was approved.
👀 What to Watch
Investors can expect the confirmed dividend payout of Rs 2 per share following this approval. The high level of shareholder support for management indicates strong confidence in the company's current strategic direction.
Vimta Labs 36th AGM: ₹2 Dividend Approved and Executive Chairman Re-appointed
Vimta Labs Limited concluded its 36th Annual General Meeting on June 25, 2026, where shareholders transacted several key business items. A dividend of ₹2 per equity share was declared for the financial year ended March 31, 2026. The meeting also confirmed the re-appointment of Dr. S P Vasireddi as Executive Chairman and Mr. Harriman Vungal as Executive Director of Operations. Additionally, the company ratified the remuneration for cost auditors for the 2024-25 and 2025-26 financial years.
Key Highlights
Declaration of a dividend of ₹2 per equity share for the financial year ended March 31, 2026
Re-appointment of Dr. S P Vasireddi as the Executive Chairman of the company
Re-appointment of Mr. Harriman Vungal as Executive Director - Operations
Ratification of cost auditors' remuneration for both FY 2024-25 and FY 2025-26
Adoption of Audited Financial Statements for the fiscal year ending March 31, 2026
👀 What to Watch
Investors should look forward to the dividend credit following the AGM approval and view the leadership continuity as a sign of operational stability. Monitor the final voting results to be published on the stock exchanges within two working days.
Vimta Labs to Hold 36th AGM on June 25, 2026; Proposes ₹2 Dividend and Leadership Re-appointments
Vimta Labs has scheduled its 36th Annual General Meeting for June 25, 2026, to approve the financial statements for FY 2025-26 and a proposed dividend of ₹2 per equity share. A key resolution includes the re-appointment of Dr. S P Vasireddi as Executive Chairman for a five-year term starting July 1, 2026, with a monthly salary of ₹18 lakh. The board also seeks ratification for cost auditor remuneration of ₹50,000 per annum for FY25 and FY26. Leadership continuity is emphasized with the re-appointment of Mr. Harriman Vungal as Executive Director of Operations.
Key Highlights
Proposed dividend of ₹2 per equity share for the financial year ended March 31, 2026
Re-appointment of Dr. S P Vasireddi as Executive Chairman for a 5-year term with a monthly salary of ₹18,00,000
Executive Chairman's commission capped at 1% of Net Profits as per Section 198 of the Companies Act
Ratification of ₹50,000 annual remuneration for Cost Auditors M/s Lavanya and Associates LLP
36th AGM to be conducted via Video Conferencing on June 25, 2026, at 10:00 A.M. IST
👀 What to Watch
Investors should monitor the AGM outcomes for confirmation of the ₹2 dividend and the long-term leadership stability provided by the Chairman's re-appointment. The continuity in management and consistent dividend payout are positive indicators for long-term shareholders.
Vimta Labs FY26 Revenue Up 19.5% to ₹4,163 Million; EBITDA Margins Strong at 35.8%
Vimta Labs reported a robust financial performance for FY26, with total income rising 19.5% YoY to ₹4,163 million and PAT increasing 16.1% to ₹775 million. The company maintained industry-leading profitability with an annual EBITDA margin of 35.8%, driven by strong demand in pharmaceutical and food testing segments. For Q4 FY26, revenue grew 16.6% YoY to ₹1,120 million, while quarterly EBITDA margins reached 37.6%. The company remains net debt-free with cash reserves of ₹650 million and is strategically expanding into biologics contract research for FY27.
Key Highlights
FY26 total income grew by 19.5% YoY to ₹4,163 million, with Q4 income rising 16.6% to ₹1,120 million.
Full-year EBITDA stood at ₹1,489 million with a healthy margin of 35.8%, among the best in the industry.
Net profit (PAT) for the full year increased by 16.1% to ₹775 million, resulting in an EPS of ₹17.4.
Maintained a net debt-free balance sheet with cash and bank balances of approximately ₹650 million.
Announced strategic entry into biologics and peptides contract research services starting in FY27.
👀 What to Watch
Investors should focus on the company's successful transition into high-growth biologics and its ability to sustain high margins despite global cost pressures. The debt-free status and strong cash position provide a solid cushion for future capacity expansions.
Vimta Labs Re-appoints Founder Dr. S. P. Vasireddi as Executive Chairman for 5-Year Term
Vimta Labs has recommended the re-appointment of its founder, Dr. S. P. Vasireddi, as Executive Chairman for a five-year term effective from July 1, 2026, to June 30, 2031. As Dr. Vasireddi is 77 years old, the appointment requires a special resolution from shareholders at the upcoming Annual General Meeting. He currently holds a significant stake of 51,97,050 equity shares in the company. This move signals leadership continuity, as he has been pivotal to the company's growth for over four decades and is the father of the current Managing Director.
Key Highlights
Re-appointment of Dr. S. P. Vasireddi as Executive Chairman for a 5-year term starting July 2026.
Dr. Vasireddi holds 51,97,050 equity shares in Vimta Labs Limited.
Special resolution required for appointment as the candidate has attained 77 years of age.
Dr. Vasireddi has over 40 years of industry experience and founded the company.
He is the father of the current Managing Director, Ms. Harita Vasireddi, ensuring family leadership continuity.
👀 What to Watch
Investors should see this as a positive sign of leadership stability and continuity of the founder's vision. No immediate action is required other than noting the upcoming shareholder vote on the special resolution.
Vimta Labs Recommends ₹2 Dividend per Share; Sets Record Date for June 18, 2026
Vimta Labs has recommended a final dividend of ₹2 per equity share for the financial year 2025-26. This payout represents a 100% dividend on the face value of ₹2 per share. The company has designated June 18, 2026, as the record date to identify eligible shareholders for this payment. Subject to shareholder approval at the Annual General Meeting, the dividend will be disbursed on or before July 8, 2026.
Key Highlights
Recommended a dividend of ₹2 per equity share for the financial year 2025-26.
The dividend payout is 100% of the face value of ₹2 per share.
Record date for determining shareholder eligibility is June 18, 2026.
Payment of dividend is scheduled to be completed on or before July 8, 2026.
👀 What to Watch
Investors interested in the dividend should hold the stock prior to the ex-dividend date to be eligible for the ₹2 per share payout. The 100% dividend reflects the company's consistent policy of sharing profits with its shareholders.
Vimta Labs Re-appoints Founder Dr. S. P. Vasireddi as Executive Chairman for 5-Year Term
Vimta Labs has recommended the re-appointment of its founder, Dr. S. P. Vasireddi, as Executive Chairman for a five-year term effective from July 1, 2026, to June 30, 2031. Given that Dr. Vasireddi is 77 years old, the appointment requires a special resolution from shareholders at the upcoming Annual General Meeting. He currently holds a significant stake of 51,97,050 equity shares in the company. This move ensures leadership continuity, as he has over 40 years of experience and is the father of the current Managing Director, Ms. Harita Vasireddi.
Key Highlights
Re-appointment of Dr. S. P. Vasireddi as Executive Chairman for a 5-year term starting July 2026.
Dr. Vasireddi holds 51,97,050 equity shares in the company as of the announcement date.
Special resolution required for approval due to the appointee reaching 77 years of age.
Dr. Vasireddi has over 40 years of industry experience and has been with the company since its inception.
👀 What to Watch
Investors should view this as a move to maintain leadership stability and continuity of the founder's strategic vision. No immediate action is required, though shareholders should track the voting results during the next Annual General Meeting.
Vimta Labs Recommends Final Dividend of ₹2 Per Share for FY 2025-26
Vimta Labs Limited has recommended a final dividend of ₹2 per equity share for the financial year 2025-26. The dividend is declared on shares with a face value of ₹2 each, representing a 100% payout on the nominal value. The company has fixed June 18, 2026, as the record date to identify eligible shareholders. Subject to shareholder approval at the upcoming AGM, the dividend is expected to be paid by July 8, 2026.
Key Highlights
Recommended final dividend of ₹2 per equity share for FY 2025-26
Dividend payout represents 100% of the face value of ₹2 per share
Record date for dividend eligibility is fixed as June 18, 2026
Payment to be processed on or before July 8, 2026, post-AGM approval
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the record date of June 18, 2026. The 100% dividend on face value indicates a stable return for long-term shareholders.
Vimta Labs FY26 Revenue Up 19.5% to Rs 4,163 Mn; Q4 PAT Rises 15.2% YoY
Vimta Labs reported a strong performance for FY26, with total income reaching Rs. 4,163 Mn, a 19.5% increase over the previous fiscal year. The company achieved its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26, driven by growth in its Pharma and Food divisions. EBITDA margins remained robust at 35.8% for the full year, while annual PAT grew 16.1% to Rs. 775 Mn. Following the divestment of its diagnostics business in late 2024, the company has successfully focused on high-margin contract research and testing services.
Key Highlights
Full-year FY26 revenue grew 19.5% YoY to Rs. 4,163 Mn compared to Rs. 3,482 Mn in FY25.
Q4 FY26 EBITDA margin expanded to 37.6% compared to 34.3% in the preceding quarter.
Annual Profit After Tax (PAT) increased to Rs. 775 Mn with a healthy margin of 18.6%.
Basic EPS for the full year improved to Rs. 17.4 from Rs. 15.0 in the previous year.
The company achieved its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26.
👀 What to Watch
Investors should note the consistent margin profile and double-digit revenue growth as signs of strong operational execution in the CRO space. The stock remains a key player to watch in the testing and research sector following its successful pivot away from diagnostics.
Vimta Labs Reports Strong FY26 Performance with 19.5% Revenue Growth and 37.6% Q4 EBITDA Margin
Vimta Labs Limited delivered a robust financial performance for FY26, with total income rising 19.5% YoY to ₹4,163 million. The company maintained strong profitability, reporting a full-year PAT of ₹775 million and an EPS of ₹17.4. Operational efficiency was particularly notable in Q4, where EBITDA margins reached 37.6%. With a very low debt-to-equity ratio of 0.01 and cash reserves of ₹650.6 million, the company is well-positioned for its ongoing expansion plans.
Key Highlights
Total Income for FY26 grew 19.5% YoY to ₹4,163 million, while Q4 income rose 16.6% YoY to ₹1,120 million.
Q4 EBITDA margins improved to 37.6% compared to 36.1% in the same quarter last year.
Full-year PAT increased by 16.1% to ₹775 million, supported by growth across Pharma, Food, and Electronics testing segments.
The company undertook a significant Capex of ₹998 million in FY26 to enhance lab infrastructure and capabilities.
Balance sheet remains exceptionally strong with total debt of only ₹33.3 million against cash equivalents of ₹650.6 million.
👀 What to Watch
Investors should note the company's consistent margin profile and minimal leverage as signs of high-quality growth. The aggressive capex cycle indicates strong future demand in the TIC (Testing, Inspection, and Certification) sector, making it a solid long-term hold.
Vimta Labs FY26 Equity Grows 20%; Announces ₹2 Dividend and US Subsidiary Incorporation
Vimta Labs reported a strong balance sheet for the financial year ended March 31, 2026, with total equity rising to ₹4,568.73 million from ₹3,788.48 million in the previous year. The Board has recommended a dividend of ₹2 per share (100% of face value) and approved the incorporation of a wholly-owned subsidiary in the USA to drive international expansion. Leadership stability is also addressed with the reappointment of Dr. S. P. Vasireddi as Executive Chairman for a five-year term starting July 2026.
Key Highlights
Recommended a dividend of ₹2 per share (100% on face value of ₹2) for FY 2025-26.
Total Assets increased by 20.5% year-on-year to ₹5,622.28 million as of March 31, 2026.
Approved the incorporation of a new wholly-owned subsidiary in the USA to expand global operations.
Reappointed Dr. S. P. Vasireddi as Executive Chairman for a 5-year term (2026-2031).
Total Equity and Reserves rose significantly to ₹4,568.73 million from ₹3,788.48 million.
👀 What to Watch
Investors should view the US expansion and consistent dividend payout as signs of management's growth confidence; the stock remains a solid hold for long-term value.
Vimta Labs Q3 FY26 Revenue Up 10.2% YoY to ₹100.5 Cr; 9M Profit Grows 16.4%
Vimta Labs reported a 10.2% YoY revenue growth in Q3 FY26, reaching ₹100.5 crores, although it experienced a 3.9% sequential decline due to operational restructuring and clinical order lags. The 9-month performance remains strong with total income rising 20.7% to ₹304.3 crores and PAT increasing 16.4% to ₹56.4 crores. The company is expanding into biologics CRDMO services, expected to commercialize in Q1 FY27, and maintains a net debt-free balance sheet. Management expects a stronger Q4 performance, aligning with historical seasonal trends.
Key Highlights
Q3 FY26 revenue grew 10.2% YoY to ₹100.5 crores, while 9M FY26 revenue rose 20.7% to ₹304.3 crores.
EBITDA for 9M FY26 stood at ₹106.8 crores with a healthy margin of 35.1%.
Recognized a one-time exceptional cost of ₹1.6 crores due to new labor law implementation.
Biologics contract research and development services are scheduled for commercialization by Q1 FY27.
EMI/EMC testing facility is operating at 80-85% utilization, with a second chamber installation on track.
👀 What to Watch
Investors should monitor the successful commercialization of the biologics segment in FY27 and the recovery of clinical research order bookings. The company's debt-free status and strong margins in the TIC sector provide a stable long-term outlook.
Vimta Labs Q3 FY26 Total Income Rises 10.2% YoY to ₹1,005 Mn; PAT Flat at ₹176 Mn
Vimta Labs reported a 10.2% YoY increase in total income for Q3 FY26, reaching ₹1,005 million, though revenue declined 3.9% on a sequential basis. Net profit remained nearly flat YoY at ₹176 million, with margins facing pressure as the EBITDA margin contracted to 34.3% from 37.6% in the previous year. The margin compression was partly attributed to exceptional items related to the impact of New Labour Codes. However, the nine-month (9M FY26) performance remains robust, with total income growing 20.7% and PAT increasing 16.4% YoY.
Key Highlights
Total Income for Q3 FY26 stood at ₹1,005 Mn, up 10.2% YoY but down 3.9% QoQ.
EBITDA margin contracted to 34.3% in Q3 FY26 compared to 37.6% in Q3 FY25.
9M FY26 Total Income grew significantly by 20.7% YoY to ₹3,043 Mn.
Net Profit for 9M FY26 increased by 16.4% YoY to ₹564 Mn with an EPS of ₹12.67.
Margins were impacted by exceptional costs related to the implementation of New Labour Codes.
👀 What to Watch
Investors should monitor the impact of the New Labour Codes on future margins to see if the current compression is transitory. While the 9-month growth trajectory is strong, the sequential dip in revenue and profit warrants a cautious watch on near-term demand.
Vimta Labs Q3 FY26 Total Income up 10.2% YoY to ₹1,005 Mn; 9M PAT Grows 16.4%
Vimta Labs reported a steady performance for Q3 FY26 with total income reaching ₹1,005 Mn, a 10.2% YoY increase. For the 9-month period (9M FY26), the company showed robust growth with revenue rising 20.7% to ₹3,043 Mn and PAT increasing 16.4% to ₹564 Mn. EBITDA margins remain healthy at 35.1% for the 9M period, supported by a strong balance sheet featuring minimal debt of ₹45.2 Mn and significant cash reserves of ₹666.6 Mn. The company continues to invest in growth, reporting a Q3 capex outflow of ₹248.3 Mn.
Key Highlights
9M FY26 Total Income grew by 20.7% YoY to ₹3,043 Mn compared to ₹2,521 Mn in 9M FY25
9M FY26 PAT increased by 16.4% YoY to ₹564 Mn with a healthy PAT margin of 18.5%
EBITDA for Q3 FY26 stood at ₹344 Mn with a margin of 34.3%, despite a ₹16 Mn exceptional item for labor codes
Maintains a very low Debt-to-Equity ratio of 0.01 with total debt of only ₹45.2 Mn
Significant infrastructure footprint with over 600,000 sq. ft. of lab space and 1,300+ employees
👀 What to Watch
Investors should view the consistent double-digit revenue growth and strong margin profile as a sign of operational efficiency in the TIC industry. The company's extremely low leverage and high cash reserves provide a strong cushion for future expansion.
Vimta Labs Q3 FY26: Revenue Grows 9.7% YoY to ₹986M; PAT Steady at ₹176M
Vimta Labs reported a 9.7% YoY growth in revenue from operations for Q3 FY26, reaching ₹986.33 million. Net profit from continuing operations remained nearly flat at ₹175.86 million compared to ₹175.16 million in the previous year, largely due to a one-time exceptional charge of ₹16.16 million related to the implementation of new labour codes. For the nine-month period, the company showed stronger performance with revenue increasing 19.4% and net profit rising 16.4% YoY. The company continues to focus on its core contract research and testing services following the divestment of its diagnostics business.
Key Highlights
Revenue from operations increased to ₹986.33 million in Q3 FY26 from ₹899.23 million in Q3 FY25.
Net profit for the quarter stood at ₹175.86 million, including a ₹16.16 million exceptional cost for gratuity adjustments under new labour codes.
9M FY26 total income reached ₹3,042.83 million, a significant jump from ₹2,521.41 million in the same period last year.
Basic EPS for the quarter was ₹3.96, compared to ₹3.93 in the year-ago period (adjusted for the 1:1 bonus issue).
The Board approved the grant of 38,269 new ESOP options to eligible employees.
👀 What to Watch
The steady revenue growth in the core testing business is positive, though margins were temporarily impacted by statutory exceptional items. Long-term investors should monitor the scalability of the National Food Testing Laboratory (PPP project) and the impact of labour code revisions on operating margins.
